FDA reports new deaths with diabetes drug Byetta
August 18, 2008 By MATTHEW PERRONE , AP Business Writer(AP) -- Federal regulators are working on a stronger label for a widely used diabetes drug marketed by Amylin Pharmaceuticals Inc. and Eli Lilly & Co. after deaths continue to be reported despite earlier government warnings.
Content from The Associated Press expires 15 days after original publication date. For more information about The Associated Press, please visit www.ap.org .
Similar stories from PHYSorg:
FDA notes heart events, tumors with Novo drug
Mar 31, 2009 |
not rated yet |
0
Exenatide promotes weight loss when added to diet and exercise
Jun 11, 2009 |
not rated yet |
0
Is inhaled insulin delivery still a possibility? Why has it been a commercial failure?
Sep 23, 2009 |
not rated yet |
0
FDA: Bristol-Myers diabetes drug appears safe
Mar 30, 2009 |
not rated yet |
0
FDA orders overdose warnings for Darvocet
Jul 07, 2009 |
not rated yet |
0



In contrast, when a natural nutrient product causes similar trouble, the answer is usually to ban that product outright.
Double standard?